PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced the appointment of Magali Taiel, MD, as Chief Medical Officer, effective immediately. Dr. Taiel replaces Barrett Katz, MD, who resigned to pursue other career opportunities. She has been Vice Presi
08:30
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée à la découverte et au développement de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, annonce la nomination du Dr Magali Taiel au poste de Directeur Médical, effective immédiatement. Le Dr Taiel remplace Barrett Katz, qui a démissionné de ses fonctions po
08:30
REDWOOD VALLEY, Calif.--(BUSINESS WIRE)-- #flowkana--At the heart of Flow Kana – California’s number one selling cannabis flower brand that both sources from, and empowers, Northern California’s locally-owned, regenerative, independent farms - is the understanding that cannabis can be a catalyst for change. On September 22nd and 23rd, 250+ visionaries representing the environment, arts, and sciences, converged at Flow Kana’s 300 acre Redwood Valley property, the Flow Cannabis Institute, to attend...
02:20
MENLO PARK, Calif.--(BUSINESS WIRE)--Ninth paragraph, first sentence of the release should read: In the group of more than 20 cancer types, the overall detection rate at 99.3 percent specificity was 55 percent (n=361/659; 95% confidence interval: 51-59%), with detection rates of 18 percent (13-25%), 43 percent (35-51%), 81 percent (73-87%), and 93 percent (87-96%) at stages I (n=185), II (n=166), III (n=134), and IV (n=148), respectively. The corrected release reads: GRAIL ANNOUNCES POSITIVE VA
01:52
SAN DIEGO & HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based IVD kits, including companion diagnostics, for patient management. The agreement grants QIAGEN non-exclusive rights to develop and globally commercialize IVD kits to be used together with Illumina’s MiSeq™ Dx and NextSeq™ 550Dx Systems. The agreeme
Mon Oct 07, 2019 23:05
MOUNT ARLINGTON, N.J.--(BUSINESS WIRE)--PanOptica announced that the company will present topline data from its Phase 1/2 clinical trial of PAN-90806 at the OIS@AAO on Thurs., Oct. 10, 2019
Mon Oct 07, 2019 23:00
PHILADELPHIA & MADISON, Wis.--(BUSINESS WIRE)-- #ASCO--Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing treatments for hormone driven cancers, today announced a Phase 2 clinical collaboration with the Wisconsin Oncology Network. This clinical collaboration will evaluate whether the addition of Apristor to the antiestrogen, fulvestrant, can enhance outcomes for patients with metastatic breast cancer whose cancer has progressed on prior therapies. The Phase...
Mon Oct 07, 2019 21:00
CAMBRIDGE, England--(BUSINESS WIRE)--Abzena launch ADC and Biologics Cascade, new ex-vivo platform approaches to allow efficacy and safety studies against clinically characterized tissue
Mon Oct 07, 2019 16:10
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that based on secondary analyses from its Phase 2 CLARITY study, adjunctive pimavanserin showed the potential to improve symptoms of sexual dysfunction experienced by patients with major depressive disorder (MDD). These additional data were presented in the poster, “Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder With Adjunctive Pimavanserin” at the 2019 Psych Congress, O
Mon Oct 07, 2019 16:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Yumanity Therapeutics, a company focused on protecting the vitality of the mind by discovering and developing transformative brain-penetrating small molecule drugs to treat neurodegenerative diseases, today announced that the first subject cohort has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability of YTX-7739 in healthy volunteers. YTX-7739, the company’s lead investigational therapy, is designed to inhibit Stearoyl-CoA-Desaturase
Mon Oct 07, 2019 15:30
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Provides Progress Updates for Liver Program Candidates AXA1125 and AXA1957
Mon Oct 07, 2019 15:30
MONTRÉAL--(BUSINESS WIRE)--MyX Therapeutics Inc, une compagnie offrant une plateforme unique de livraison ciblant les muqueuses, annonce de nouvelles données provenant d’études précliniques confirmant que sa nouvelle formulation, constituée de nanoparticules ciblant la muqueuse oculaire, peut être administrée une fois par semaine sous forme de gouttes ophtalmiques. Le Dr Frank Gu, co-fondateur et Chef scientifique (CSO), présentera ces données, aujourd'hui 7 octobre 2019, à la 9ème conférence a
Mon Oct 07, 2019 15:00
LEXINGTON, Mass.--(BUSINESS WIRE)-- #aldeyratherapeutics--Aldeyra Therapeutics will discuss its Phase 3 ocular programs on Thursday, October 10 at the Ophthalmology Innovation Summit in San Francisco.
Mon Oct 07, 2019 15:00
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex's non-viral vector delivery system is aligned with industry research.
Mon Oct 07, 2019 15:00
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--At CHEST 2019, Veracyte will announce new clinical data for the first noninvasive nasal swab test to target early lung cancer detection.
Mon Oct 07, 2019 15:00
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Igor Nasonkin, Ph.D., Principal Investigator and Director of R&D, will serve as a co-Chair of the Neural Differentiation, Transplantation, and Regeneration Nanosymposium, in addition to presenting data on the Company’s Vision Restoration Program at Neuroscience 2019,...
Mon Oct 07, 2019 15:00
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced updated median overall survival data from its Phase 1/2 KEYNOTE-046 study in metastatic, castration-resistant prostate cancer (mCRPC). This trial is being conducted in conjunction with Merck (known as MSD outside the U.S. and Canada) and is evaluating ADXS-PSA, one of Advaxis’ Listeria monocy
Mon Oct 07, 2019 15:00
MONTREAL--(BUSINESS WIRE)-- #MyXdelivery--MyX Therapeutics Inc, a unique enabling mucosal delivery platform company, announces new data from preclinical studies confirming MyX’s mucosal targeting nanoparticle eye drop formulation allows once-a-week dosing. Dr Frank Gu, co-founder and Chief Scientific Officer (CSO), will present these data, today October 7, 2019 at the 9th annual Partnership Opportunities in Drug Delivery (PODD) conference, at 5:45 p.m. Eastern Time. "MyX-001 data suggests a significant...
Mon Oct 07, 2019 15:00
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM), (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that its partner Yakult Honsha Co., Ltd. (Yakult) has dosed the first patient in a Phase 1b Japanese bridging study evaluating COPIKTRA® (duvelisib) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lym
Mon Oct 07, 2019 14:00
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced results from a study of the company’s ASCEND investigational drug-coated sinus balloon. The ASCEND study is the first prospective, randomized, double-blind, multi-center trial designed to assess the safety and efficacy of Intersect ENT’s drug-coated sinus balloon used to dilate the frontal sinus ostium. The investig
Mon Oct 07, 2019 14:00
米デラウェア州ウィルミントン--(BUSINESS WIRE)--（ビジネスワイヤ） -- インサイト（Nasdaq:INCY）は、主要評価項目に関する最終結果を含め、治療歴のある局所進行性／転移性胆管がんの治療薬としてペミガチニブを評価する第2相FIGHT-202試験の最新結果を発表します。ペミガチニブは、選択的な線維芽細胞増殖因子受容体（FGFR）阻害剤です。FGFR2遺伝子の融合／再構成を持つ患者（コホートA）で、ペミガチニブによる単剤療法は、中央値15カ月のフォローアップ期間で36パーセントの全奏功率（ORR）（主要評価項目）、6.9カ月の無増悪生存期間（PFS）中央値（副次的評価項目）をもたらしました。ペミガチニブの忍容性は全般的に良好でした。 これらの試験結果は、スペインのバルセロナで開催中の2019年欧州臨床腫瘍学会（ESMO）学術集会の最新演題口頭セッションで、本日9月27日の中央ヨーロッパ標準時午後3時00分～3時15分（米国東部標準時午前9時00分～9時15分）にマドリード・オーディトリアム（ホール2）で発表されます。アブストラクトは#LBA40です。 インサイト
Mon Oct 07, 2019 13:56
MUNICH & GARCHING, Germany--(BUSINESS WIRE)--ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, announced today that ITM´s subsidiary, ITG Isotope Technologies Garching GmbH (ITG) and Nordic Nanovector ASA (OSE: NANO) have signed long-term global supply agreements for the medical radioisotope no-carrier-added Lutetium-177 (n.c.a. 177Lu) EndolucinBeta® to support R&D, clinical and commercial supply of Betalutin® (177Lu-Lilotomab-Satetraxet
Mon Oct 07, 2019 11:14
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου